Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

• Market Cap: €1.06B
• Dividend Yield: 0.94%
• Average Volume (3M): 108.96K
• Price to Earnings (P/E): 28.9
• Beta (1Y): 1.13
• Revenue Growth: 9.42%
• EPS Growth: 9.54%
• Country: DE
• Employees: 1,085
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.19
• Shares Outstanding: 63,515,797
• 10 Day Avg. Volume: 81,969
• 30 Day Avg. Volume: 108,959
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €22.47
• Price Target Upside: 27.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 66 Neutral
• Price Target: €19.00 ▲(7.59% Upside)

Eckert & Ziegler Strahlen und Medizintechnik's overall stock score is primarily driven by its strong financial performance, characterized by robust revenue growth and solid profitability. However, technical analysis indicates a bearish trend, and the valuation suggests the stock is relatively expensive. The absence of earnings call data and corporate events limits additional insights.

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company Description

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.

How the Company Makes Money

Eckert & Ziegler generates revenue through multiple streams, primarily by selling its advanced medical devices and radiopharmaceuticals to hospitals, clinics, and healthcare providers. The company also earns income from long-term contracts with healthcare institutions for the provision of nuclear medicine services and the supply of isotopes. Significant partnerships with healthcare organizations and research institutions enhance its market reach and product development capabilities. Additionally, EUZ may benefit from government contracts and grants related to healthcare innovation and technology advancements, which contribute to its overall earnings.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary

Eckert & Ziegler Strahlen und Medizintechnik exhibits strong financial health with impressive revenue growth and solid profitability metrics. The balance sheet is stable, though rising debt levels warrant attention. Cash flow generation is robust, supporting the company's growth trajectory. Overall, the company is well-positioned in the medical devices industry, but careful management of cost pressures and debt is essential to sustain its financial performance.

Income Statement

Eckert & Ziegler Strahlen und Medizintechnik shows strong revenue growth with a TTM (Trailing-Twelve-Months) growth rate of 94.8%, indicating robust expansion. The company maintains healthy profitability with a gross profit margin of 48.05% and a net profit margin of 11.62%. EBIT and EBITDA margins are also solid at 21.58% and 27.70%, respectively, reflecting efficient operations. However, the slight decline in gross profit margin compared to previous periods suggests potential cost pressures.

Balance Sheet

The balance sheet is stable with a manageable debt-to-equity ratio of 0.25, indicating prudent leverage. Return on equity (ROE) is strong at 14.43%, showcasing effective use of equity capital. The equity ratio stands at 51.16%, reflecting a solid equity base. However, the increase in total debt over recent periods could pose a risk if not managed carefully.

Cash Flow

The company demonstrates strong cash flow generation with a free cash flow growth rate of 8.52% in the TTM period. The operating cash flow to net income ratio is high at 0.93, indicating efficient cash conversion. The free cash flow to net income ratio of 0.74 suggests good cash profitability. Despite these strengths, the volatility in free cash flow growth over the years highlights potential fluctuations in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	299.26M	295.85M	246.09M	222.26M	180.44M	176.14M
Gross Profit	143.71M	143.16M	116.34M	106.78M	91.08M	86.53M
EBITDA	85.70M	77.38M	59.67M	57.90M	56.68M	43.05M
Net Income	36.64M	33.28M	26.30M	29.28M	34.53M	21.29M
Balance Sheet
Total Assets	438.88M	442.40M	439.36M	416.84M	347.73M	292.00M
Cash, Cash Equivalents and Short-Term Investments	112.37M	118.36M	68.00M	82.70M	95.02M	88.61M
Total Debt	48.57M	55.34M	56.30M	49.59M	26.97M	20.40M
Total Liabilities	212.82M	217.18M	215.27M	203.21M	155.20M	143.08M
Stockholders Equity	224.60M	223.45M	222.18M	212.07M	187.39M	147.82M
Cash Flow
Free Cash Flow	56.77M	49.38M	21.12M	3.17M	5.00M	27.88M
Operating Cash Flow	74.92M	66.57M	46.95M	34.30M	33.85M	36.79M
Investing Cash Flow	-28.46M	-16.59M	-42.74M	-41.04M	-23.59M	-13.35M
Financing Cash Flow	-20.79M	-9.99M	-9.28M	-5.71M	-6.06M	-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 17.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Neutral. The current price of 17.66 is above the 20-day moving average (MA) of 17.43, above the 50-day MA of 17.47, and below the 200-day MA of 19.14, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 49.25 is Neutral, neither overbought nor oversold. The STOCH value of 77.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	66 Neutral	€1.06B	28.87	17.61%	0.94%	9.42%	9.54%
COP	60 Neutral	€1.28B	68.59	2.87%	0.21%	1.16%	-43.53%
FYB	60 Neutral	€411.78M	5.89	-34.48%	―	-14.84%	-338.52%
BIO3	52 Neutral	€1.33B	―	―	0.14%	-18.82%	-113.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BIO	51 Neutral	€1.31B	64.15	―	0.11%	-18.82%	-113.85%
EVT	49 Neutral	€1.19B	―	-16.75%	―	-1.41%	9.05%